TABLE 1.
Antimicrobial susceptibility of clinical isolates
| Antibiotica | Susceptibility (MIC [μg/ml])b |
|||||
|---|---|---|---|---|---|---|
| P. aeruginosa | P. aeruginosa | K. pneumoniae | P. stuartii | S. epidermidis | S. haemolyticus | |
| OXA | NA | NA | NA | NA | R (≥4) | S (≤0.25) |
| PIP | R (≥128) | R (≥128) | R | R | R | S |
| PIP-TAZ | R (≥128) | R (≥128) | R (≥128) | R (≥128) | R | S |
| CAZ | S (4) | R (≥64) | R (≥16) | R (≥16) | R | R |
| CAF-AVI | S (2) | R (≥256) | S (1) | S (0.5) | NA | NA |
| IMI | R (≥16) | R (≥16) | R (≥16) | R (≥16) | R | S |
| AZT | R (≥64) | R (≥64) | NA | NA | NA | NA |
| CEF | R (≥64) | R (≥64) | R (32) | S (≤1) | R | S |
| MER | R (≥16) | R (≥16) | R (≥16) | I (4) | R | S |
| CIP | R (≥2) | R (≥2) | R (≥4) | R | R | S |
| LEV | R | R | R | R | R (≥8) | S (≤0.12) |
| GEN | R (≥16) | R (≥16) | S (≤16) | R (≤1) | R (8) | S (≤0.5) |
| TOB | R (≥16) | R (≥16) | R (8) | R (2) | R | S |
| AMI | R (16) | R (≥64) | I (≤2) | I (≤16) | NA | NA |
| FOS | R (≥256) | R (≥256) | NA | NA | S (≤8) | R (≥128) |
| COL | S (0.5) | S (1) | NA | NA | NA | NA |
| DOX | NA | NA | NA | NA | S (≤1) | S (≤1) |
| RIF | NA | NA | NA | NA | S (≤0.03) | S (≤0.03) |
| VAN | NA | NA | NA | NA | S (2) | S (≤0.5) |
| DAP | NA | NA | NA | NA | S (0.25) | S (≤0.12) |
| TMP-SMX | NA | NA | S (≤20) | R (≥320) | S (20) | S (≤10) |
a
OXA, oxacillin; PIP, piperacillin; PIP-TAZ, piperacillin-tazobactam; CAZ, ceftazidime; CAZ-AVI, ceftazidime-avibactam; IMI, imipenem; AZT, aztreonam; CEF, cefepime; MER, meropenem; CIP, ciprofloxacin; LEV, levofloxacin; GEN, gentamicin; TOB, tobramycin; AMI, amikacin; FOS, fosfomycin; COL, colistin; DOX, doxycycline; RIF, rifampin; VAN, vancomycin; DAP, daptomycin; TMP-SMX, trimethoprim-sulfamethoxazole.
b
R, resistant; S, susceptible; NA, not available. Interpretations according to CLSI guidelines.